{
  "title": "BioXcel will use $260M finance deal to expand indications for schizophrenia drug - FierceBiotech",
  "url": "https://www.fiercebiotech.com/biotech/bioxcel-enters-260m-finance-deal-accelerate-growth-though-prerequisites-must-be-met-unlock",
  "date": "Wed, 20 Apr 2022 13:30:00 GMT",
  "content": "<a href=\"https://www.fiercebiotech.com/biotech/bioxcel-enters-260m-finance-deal-accelerate-growth-though-prerequisites-must-be-met-unlock\" target=\"_blank\">BioXcel will use $260M finance deal to expand indications for schizophrenia drug</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">FierceBiotech</font>",
  "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1289080804.jpg?VersionId=vvJRu4mUUICrSOMUaUfLSdgbxwYkvW4J",
  "description": "BioXcel Therapeutics aims to become the leading artificial-intelligence-enabled neuroscience company, and it may have just received the financing to get thereâ€“but terms apply. | The commercial-stage biopharmaceutical entered a $260 million long-term financing agreement with Oaktree Capital Management and Qatar Investment Authority to accelerate growth and commercially launch a new drug, in return for a share of the profits of any approved therapies.",
  "publisher": "Google News Finance USA",
  "publisherUrl": "https://news.google.com/search?q=finance&hl=en-US&gl=US&ceid=US:en"
}